RXi Pharmaceuticals initiates consumer/functional testing program with RXI-231
RXi Pharmaceuticals announced the initiation of a consumer/functional testing program with RXI-231, a cosmetic ingredient based on sd-rxRNA that targets tyrosinase. The cosmetic product that will be tested is a gel formulation designed to aid in the reduction of pigmentation and thereby improving skin appearance. The consumer testing program will evaluate the use and consumer acceptability of RXI-231. Three studies are planned under this program. The first two studies in volunteers are performed to determine irritation and sensitization potential of the gel product containing RXI-231 when applied to the skin. The RXI-231 gel is intended to improve the appearance of existing areas of hyperpigmentation on the skin. Therefore, a third study will investigate the potential of the product to improve the appearance of skin pigmentation induced by UV exposure.